Who
J. Anthony Ware
Director
Company insider
Files Form 4 as: Director, First Tracks Biotherapeutics; Director, AnaptysBio.
In numbers
- Trades disclosed
- 69
- Buys
- 1
- Sells
- 2
- Bought
- $51K
- Sold
- $3.7M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 22 Aug 2017
- Last trade
- 2 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 4 Sep 2026 | TRAX First Tracks BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $225K39,265 at $5.74 | filing |
| 2 Sep 2026filed 4 Sep 2026 | TRAX First Tracks BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $1.8M39,265 at $44.78 | filing |
| 2 Sep 2026filed 4 Sep 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,571 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,571 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,694 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,694 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | TRAX First Tracks BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $225K39,265 at $5.74 | filing |
| 2 Sep 2026filed 4 Sep 2026 | TRAX First Tracks BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $1.8M39,265 at $44.78 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
News
Financial Review: Myriad Genetics (NASDAQ:MYGN) & AnaptysBio (NASDAQ:ANAB)ANAB · tickerreport.com · 20 Oct 2026First Tracks Biotherapeutics Announces $200 Million Private PlacementTRAX · manilatimes.net · 15 Oct 2026First Tracks Biotherapeutics Shares Rise 9% On Positive Celiac Disease Trial DataTRAX · rttnews.com · 12 Oct 2026FinancialContent - First Tracks Biotherapeutics, Inc. - Ordinary Shares (Nasdaq:TRAX) Stock QuoteTRAX · financialcontent.com · 12 Oct 2026
0 headlines in the last 90 days name J. Anthony Ware; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.